MedTrace Logo

A Pilot Study for the Treatment of Iris Neovascularization With Macugen

NCT00295828 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2008-09-04

No results posted yet for this study

Summary

The purpose of this study is to determine if a drug called Macugen may help to stop the growth of abnormal blood vessels on the iris that has occurred in the eye(s) as part of diabetic retinopathy.

Conditions

Interventions

OTHER

Pegaptanib Sodium Injection/Panretinal Photocoagulation

Pegaptanib Sodium Injection is a single dose prefilled syringe and is formulated as a 3.47 mg/mL solution. Combined with an ocular laser procedure.

PROCEDURE

Panretinal Photocoagulation (PRP)

Ocular Laser Procedure

Sponsors & Collaborators

  • Eyetech Pharmaceuticals

    collaborator INDUSTRY

  • Hermann Eye Center

    lead OTHER

Principal Investigators

  • Robert M Feldman, MD · Hermann Eye Fund & University of Texas -- Houston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00295828 on ClinicalTrials.gov